CYTEL ANNOUNCES NOTICE OF ALLOWANCE FOR PATENT APPLICATION COVERING CARBOHYDRATE MANUFACTURING TECHNOLOGY.SAN DIEGO--(BUSINESS WIRE)--Jan. 17, 1996--Cytel Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : CYTL) today announced a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application covering core technology for Cytel's enzymatic synthesis process for manufacturing of complex carbohydrates complex carbohydrates, n.pl polysaccharides; nutritional compounds composed of multiple monosaccharide (simple sugar) building blocks. Complex carbohydrates include starches, glycogen, and cellulose. . The allowed claims cover technology discovered by Dr. Chi-Huey Wong of The Scripps Research Institute and licensed to Cytel. Dr. Wong's technology is recognized for its ability to dramatically lower the cost of production of complex carbohydrates by in situ In place. When something is "in situ," it is in its original location. generation of nucleotide-sugars, key substrates used in enzymatic synthesis of carbohydrates. The allowed claims are applicable to the manufacture of carbohydrates containing the sugars N-acetyl-glucosamine and N-acetyl-galactosamine. These represent two of the six major sugars found in biologically active carbohydrates which are targets for design and commercialization of carbohydrate products. Cytel and Dr. Wong have maintained a research collaboration and licensing relationship since October 1991. When issued this patent will add to Cytel's proprietary position covering enzymatic synthesis of carbohydrates, which now includes 14 issued U.S. patents, one Notice of Allowance and 27 pending U.S. patent applications. Cytel's enzymatic synthesis technology is used in the manufacture of Cylexin(TM), currently in Phase II clinical trials for treatment of reperfusion injury reperfusion injury damage to renal blood vessels during periods of hypotension does not become apparent until reperfusion occurs in the recovery stage of the vascular incident. associated with lung surgery Lung Surgery Definition Lung surgery includes a variety of procedures used to diagnose or treat diseases of the lungs. Biopsies are performed to extract a small amount of tissue for diagnosis, resections remove a portion of lung tissue, and other and myocardial infarction myocardial infarction: see under infarction. . On January 2, Cytel announced a collaboration with Abbott Laboratories to develop manufacturing processes for the production of certain carbohydrates. Cytel intends to further leverage its core enzymatic synthesis technology for commercialization of other carbohydrate products. Cytel Corporation, founded in 1987, is a leader in the discovery, design and development of immunotherapeutics, a new class of drugs which the Company believes will be more selective and have fewer side effects Side effects Effects of a proposed project on other parts of the firm. than drugs currently on the market. Utilizing Cytel's advanced understanding of the immune system's operation both in disease and in health, the Company is developing drug candidates under two distinct approaches: the cell adhesion program is directed to the suppression of an inappropriate immune response immune response n. An integrated bodily response to an antigen, especially one mediated by lymphocytes and involving recognition of antigens by specific antibodies or previously sensitized lymphocytes. to treat inflammatory diseases including reperfusion injury, and the immune stimulation program is directed to the development of therapeutic vaccines to treat infectious diseases and cancers. CONTACT: Karin Eastham Vice President and Chief Financial Officer (619) 552-3000 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion